Abstract
The presence of microRNAs (miRNAs) and their ease of detection in body fluids including serum and whole blood have opened new avenues for developing novel non-invasive methods for diagnostics and therapeutic applications for both infectious and noninfectious diseases. Blood-borne infectious viral diseases pose challenge to public health at large and, especially to health care workers, emergency responders and public safety personnel. Several studies have explored these newly identified miRNAs in blood borne infectious diseases for various purposes. This review highlights and focuses only on some of the available literature on the patient associated cellular miRNAs in blood-borne viral diseases and its occasional extrapolation to infected cell cultures as it relates to blood-borne hepatitis C virus (HCV), hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Where appropriate, this review further points to the potential of miRNAs as non-invasive early disease detection biomarkers for these viral infections as well as possible prospects and challenges of miRNA-based therapies in treating these viral infections.
MicroRNA
Title:MicroRNAs and Major Blood-borne Infectious Viral Diseases
Volume: 2 Issue: 3
Author(s): Neetu Dahiya and Chintamani D. Atreya
Affiliation:
Keywords: Blood-borne, diseases, HBV, HCV, HIV-1, microRNA.
Abstract: The presence of microRNAs (miRNAs) and their ease of detection in body fluids including serum and whole blood have opened new avenues for developing novel non-invasive methods for diagnostics and therapeutic applications for both infectious and noninfectious diseases. Blood-borne infectious viral diseases pose challenge to public health at large and, especially to health care workers, emergency responders and public safety personnel. Several studies have explored these newly identified miRNAs in blood borne infectious diseases for various purposes. This review highlights and focuses only on some of the available literature on the patient associated cellular miRNAs in blood-borne viral diseases and its occasional extrapolation to infected cell cultures as it relates to blood-borne hepatitis C virus (HCV), hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Where appropriate, this review further points to the potential of miRNAs as non-invasive early disease detection biomarkers for these viral infections as well as possible prospects and challenges of miRNA-based therapies in treating these viral infections.
Export Options
About this article
Cite this article as:
Dahiya Neetu and Atreya D. Chintamani, MicroRNAs and Major Blood-borne Infectious Viral Diseases, MicroRNA 2013; 2 (3) . https://dx.doi.org/10.2174/2211536602666131118224225
DOI https://dx.doi.org/10.2174/2211536602666131118224225 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
Call for Papers in Thematic Issues
Modulatory Roles of Non-coding RNAs in cancer therapy
This thematic issue aims to elucidate the most recent research on ncRNAs in CRCs and discuss the importance and difficulties that may arise in applying this tool on a regular clinical basis.read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
D-RNAi (Messenger RNA-antisense DNA Interference) as a Novel Defense System Against Cancer and Viral Infections.
Current Cancer Drug Targets Frailty of Older Age: The Role of the Endocrine - Immune Interaction
Current Pharmaceutical Design Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine SCAP/SREBPs are Central Players in Lipid Metabolism and Novel Metabolic Targets in Cancer Therapy
Current Topics in Medicinal Chemistry Editorial [Hot topic: Novel Proteins and Pathways as Anti-Cancer Therapeutic Targets (Guest Editor: Q. Ping Dou)]
Current Protein & Peptide Science Patent Selections:
Current Biomarkers (Discontinued) Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Current Pharmaceutical Design A Steroidal Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitor Triggers Pro-apoptotic Signaling and Induces Apoptosis in Prostate and Lung Tumor Cells
Anti-Cancer Agents in Medicinal Chemistry Gut Emotions - Mechanisms of Action of Probiotics as Novel Therapeutic Targets for Depression and Anxiety Disorders
CNS & Neurological Disorders - Drug Targets ABC Subfamily D Proteins and Very Long Chain Fatty Acid Metabolism as Novel Targets in Adrenoleukodystrophy
Current Drug Targets Prostaglandin E<sub>2</sub> Receptor 4 (EP4): A Promising Therapeutic Target for the Treatment of Cancer and Inflammatory Diseases
Current Chemical Biology PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications
Current Radiopharmaceuticals Surface Modification: Approaches and Utilities
Current Applied Polymer Science Agents Targeting Prostate Cancer Bone Metastasis
Anti-Cancer Agents in Medicinal Chemistry Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders
Current Protein & Peptide Science Strategies for Skeletal Muscle Targeting in Drug Discovery
Current Pharmaceutical Design Is Red Meat Required for the Prevention of Iron Deficiency Among Children and Adolescents?
Current Pediatric Reviews Discovery of New Aminosubstituted Pyrrolopyrimidines with Antiproliferative Activity Against Breast Cancer Cells and Investigation of their Effect Towards the PI3Kα Enzyme
Anti-Cancer Agents in Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets